Chen et al. evaluated 68Ga-P3, a hybrid tracer containing an ODAP-Urea-based PSMA-targeting moiety, a radiometal chelator, and an ICG analog, in 16 prostate cancer patients under three different dosing regimens (10 μg/kg, 20 μg/kg, and 40 μg/kg) [58]. This evidence concerns the gene FOLH1 and prostate cancer.